公开(公告)号：WO2015054781A1

公开(公告)日：2015-04-23

申请号：PCT/CA2014/050952

申请日：2014-10-03

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HEDLEY, David W. ,  LOHSE, Ines ,  MASON, Jacqueline M. ,  BRAY, Mark R.

IPC: A61K31/5377 ,  A61K31/416 ,  A61P35/00 ,  C07D413/14

CPC classification number: A61K31/5377 ,  A61K31/7068 ,  A61K33/24 ,  A61K45/06 ,  C07D403/08 ,  C07D413/14 ,  A61K2300/00

Abstract: The invention is related to a method of treating a subject with pancreatic cancer with administration of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明涉及通过施用结构式（I）表示的化合物或其药学上可接受的盐来治疗患有胰腺癌的受试者的方法。

公开(公告)号：WO2021203190A1

公开(公告)日：2021-10-14

申请号：PCT/CA2021/050452

申请日：2021-04-05

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： FLETCHER, Graham ,  MASON, Jacqueline M. ,  BRAY, Mark R.

IPC: A61K31/5377 ,  A61K39/395 ,  A61P35/00 ,  C07D413/10 ,  C07K16/28

Abstract: Provided herein are methods of treating triple negative breast cancer using an effective amount of Compound (I) represented by the formula: or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor, wherein the checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor. Uses of an effective amount of Compound [I] and an effective amount of an immune checkpoint inhibitor, wherein the checkpoint inhibitor is a PD-1inhibitor or a PD-L1 inhibitor for treating triple negative breast cancer are also provided herein.

公开(公告)号：WO2020146946A1

公开(公告)日：2020-07-23

申请号：PCT/CA2020/050042

申请日：2020-01-16

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： BROKX, Richard ,  MASON, Jacqueline M. ,  BRAY, Mark R.

IPC: C07K16/28 ,  A61K39/395 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  A61P37/06 ,  C12N15/13 ,  C12P21/08

Abstract: The invention provides novel anti-LILRB3 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer, autoimmune disease, or allergic inflammation. This invention can also be used to modulate osteoclast differentiation.

公开(公告)号：WO2019046949A1

公开(公告)日：2019-03-14

申请号：PCT/CA2018/051086

申请日：2018-09-07

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： MASON, Jacqueline M. ,  BRAY, Mark R. ,  MAK, Tak Wah ,  FLETCHER, Graham

IPC: A61K31/5377 ,  A61K39/395 ,  A61P35/00 ,  C07D413/10

Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula (Formula (I)) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.

公开(公告)号：WO2021226707A1

公开(公告)日：2021-11-18

申请号：PCT/CA2021/050645

申请日：2021-05-10

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： BRAY, Mark R. ,  LI, Sze-wan

IPC: C07D495/04 ,  A61K31/194 ,  A61K31/4365 ,  A61P35/00 ,  C07C59/255

Abstract: A novel salt form of Compound (I) represented by the following structural formula, and its corresponding pharmaceutical compositions, are disclosed. (I), Particular single crystalline forms of 1:1 Compound (I) tartrate salt are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating cancer in a subject.

公开(公告)号：WO2020181376A1

公开(公告)日：2020-09-17

申请号：PCT/CA2020/050321

申请日：2020-03-11

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： BROKX, Richard ,  MASON, Jacqueline M. ,  BRAY, Mark R.

IPC: C07K16/18 ,  A61K39/395 ,  C12N15/13 ,  C12P21/08

Abstract: The invention provides novel anti-TSG-6 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.

公开(公告)号：WO2016065461A1

公开(公告)日：2016-05-06

申请号：PCT/CA2015/051024

申请日：2015-10-09

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： LAUFER, Radoslaw ,  NG, Grace ,  BROKX, Richard ,  PAULS, Heinz W. ,  LI, Sze-wan ,  MASON, Jacqueline M. ,  BRAY, Mark R.

IPC: C07D487/04 ,  A61K31/519 ,  A61P29/00 ,  A61P35/00 ,  A61P37/06

CPC classification number: A61K31/519 ,  A61K45/06 ,  C07D487/04

Abstract: The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).

Abstract translation: 本发明是由结构式（I）表示的化合物：（I）; 或其药学上可接受的盐。 这里提供了变量的值。 还包括药物组合物，其包含由结构式（I）表示的化合物和药学上可接受的载体或稀释剂以及用结构式（I）的化合物治疗患有癌症的受试者的方法。

公开(公告)号：WO2021207828A1

公开(公告)日：2021-10-21

申请号：PCT/CA2021/050483

申请日：2021-04-12

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： BRAY, Mark R. ,  MASON, Jacqueline M. ,  WEI, Xin ,  DUNCAN, Gordon

IPC: A61K31/4436 ,  A61P37/02 ,  C07D495/04

Abstract: Disclosed herein is a method of treating a subject with aberrant cytokine release from a disease or condition or at risk of developing aberrant cytokine release from a disease or condition. The method comprises administering to the subject an effective amount of a compound represented by structural formula (I): (I) or a pharmaceutically acceptable salt thereof. The variables in structural formula (I) are as described herein.

公开(公告)号：WO2021108918A1

公开(公告)日：2021-06-10

申请号：PCT/CA2020/051668

申请日：2020-12-04

Applicant: UNIVERSITY HEALTH NETWORK ,  BRAY, Mark R. ,  MASON, Jacqueline M. ,  FLETCHER, Graham

Inventor： BRAY, Mark R. ,  MASON, Jacqueline M. ,  FLETCHER, Graham

IPC: A61K31/5377 ,  A61K31/194 ,  A61P35/02 ,  C07C57/15 ,  C07D413/14

Abstract: The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma, or myelodysplastic syndrome by administration of Compound (I): (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：WO2020163962A1

公开(公告)日：2020-08-20

申请号：PCT/CA2020/050195

申请日：2020-02-14

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： BROKX, Richard ,  MASON, Jacqueline M. ,  BRAY, Mark R.

IPC: C07K16/28 ,  A61K39/395 ,  A61P31/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  C12N15/13 ,  C12N5/10 ,  C12P21/08

Abstract: The invention provides novel anti-FCMR antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.